2021
The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer.
Lee N, Sherman E, Schöder H, McBride S, Yu Y, Kang J, Tsai C, Gelblum D, Boyle J, Singh B, Cohen M, Cracchiolo J, Ganly I, Dunn L, Kriplani A, Fetten J, Michel L, Wong R, Pfister D, Riaz N. The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer. Journal Of Clinical Oncology 2021, 39: 6019-6019. DOI: 10.1200/jco.2021.39.15_suppl.6019.Peer-Reviewed Original ResearchPositron emission tomographyGrade 1Locoregional controlNodal diseaseOropharyngeal carcinomaOPC patientsGrade 2Primary siteGrade 3 adverse eventsWeight lossDe-escalated patientsGross nodal diseaseRecurrent nodal diseaseResolution of hypoxiaSuccessful salvage surgeryExcellent locoregional controlOverall survival rateSpecific treatment responsesPatient-specific treatment responsesConcurrent chemotherapyDefinitive doseMucositis ratesAdditional therapySalvage surgeryAdverse events
2019
Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer
Fan D, Ma J, Bell AC, Groen AH, Olsen KS, Lok BH, Leeman JE, Anderson E, Riaz N, McBride S, Ganly I, Shaha AR, Sherman EJ, Tsai CJ, Kang JJ, Lee NY. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer 2019, 126: 444-452. PMID: 31593317, PMCID: PMC7302673, DOI: 10.1002/cncr.32548.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantDose-Response Relationship, RadiationDoxorubicinFemaleFollow-Up StudiesHumansIndazolesMaleMiddle AgedPaclitaxelProgression-Free SurvivalPyrimidinesRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesSulfonamidesThyroid Carcinoma, AnaplasticThyroid GlandThyroid NeoplasmsThyroidectomyTumor BurdenConceptsLocoregional progression-free survivalRole of radiotherapyAnaplastic thyroid cancerTreatment of patientsOverall survivalAdverse eventsMetastatic diseaseTrimodal therapyThyroid cancerAcute grade 3 adverse eventsAdvanced anaplastic thyroid cancerGrade 3 adverse eventsPostoperative RTDistant metastasis-free survivalTrimodal treatment approachAcceptable toxicity profileProgression-free survivalLate adverse eventsLocal tumor controlMetastasis-free survivalLong-term outcomesLPFS ratesOS benefitConcurrent chemoradiationSystemic agents